DDInter1640 DDInter1940
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Saquinavir {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vismodegib
Saquinavir {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Saquinavir {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Vismodegib
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Saquinavir {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Saquinavir {u} (Compound) binds {v} (Gene) ORM1
ORM1 {u} (Gene) interacts with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vismodegib
Saquinavir {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Saquinavir may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Saquinavir (Compound) binds ALB (Gene) and ALB (Gene) is bound by Vismodegib (Compound)
Saquinavir (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Saquinavir may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Vismodegib (Compound)
Saquinavir (Compound) binds ALB (Gene) and ALB (Gene) interacts with ORM1 (Gene) and ORM1 (Gene) is bound by Vismodegib (Compound)
Saquinavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Saquinavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Saquinavir (Compound) binds ORM1 (Gene) and ORM1 (Gene) interacts with ALB (Gene) and ALB (Gene) is bound by Vismodegib (Compound)
Saquinavir (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Saquinavir may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)